| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Lindleyin targets estrogen receptors, specifically ERα and ERβ. It acts as an agonist for both receptor subtypes, mediating hormonal effects through these nuclear receptors. The compound binds to ERα with estrogenic activity, and this binding can be completely reversed by 4-hydroxytamoxifen, a known ER antagonist. By activating estrogen receptors, Lindleyin can modulate gene transcription and trigger estrogen-responsive biological pathways. Beyond its estrogenic activity, Lindleyin also exhibits neuroprotective properties, suggesting additional mechanisms of action that may involve antioxidant pathways and protection against oxidative stress-induced neuronal damage.
|
|---|---|
| ln Vitro |
In vitro studies have demonstrated that Lindleyin exhibits estrogenic activity through its binding to ERα. Using fluorescence polarization assays, it has been shown that Lindleyin binds to ERα in vitro, confirming its direct interaction with the receptor. A herbal extract of Rhei rhizoma, which contains Lindleyin as a major component, acts as an agonist for both ERα and ERβ. The estrogenic activity of Lindleyin is completely reversed by the ER antagonist 4-hydroxytamoxifen, confirming the receptor-mediated nature of its effects. Additionally, Lindleyin has demonstrated neuroprotective effects against hydrogen peroxide-induced cell injury in vitro, indicating its potential to protect cells from oxidative damage.
|
| ln Vivo |
In vivo activity of Lindleyin has been studied using the vitellogenin assay system in the freshwater fish Oryzias latipes (Japanese medaka). Exposure of male medaka to Rhei rhizoma extract resulted in a significant increase in serum vitellogenin levels, a biomarker of estrogenic activity. This confirms that the phytoestrogenic components, including Lindleyin, are bioavailable and active in vivo. Furthermore, Lindleyin has demonstrated neuroprotective effects in the MPTP-induced Parkinson's disease model in C57BL/6 mice, suggesting its potential for treating neurodegenerative conditions. These in vivo studies support the compound's potential therapeutic applications in hormone-related and neurodegenerative disorders.
|
| Enzyme Assay |
Non-cell-based receptor binding assays for Lindleyin typically use fluorescence polarization to assess its interaction with ERα. In this assay, purified ERα protein is incubated with a fluorescently labeled estrogen receptor ligand and varying concentrations of Lindleyin. The compound's ability to displace the labeled ligand from the receptor is measured by changes in fluorescence polarization. Binding affinity (IC50 or Ki) is determined from dose-response curves. Alternatively, radioligand binding assays using [3H]-estradiol and ERα-containing preparations can be used. These cell-free assays confirm direct receptor binding and provide quantitative measures of affinity.
|
| Cell Assay |
Cellular assays for Lindleyin utilize ER-positive cell lines to assess estrogenic activity. Cells are treated with the compound at various concentrations, and estrogen-responsive reporter gene assays (e.g., luciferase under an estrogen response element promoter) are employed to measure transcriptional activation. Alternatively, the expression of endogenous estrogen-responsive genes (e.g., pS2, progesterone receptor) is measured by qPCR. For neuroprotection studies, neuronal cell lines are treated with Lindleyin prior to exposure to hydrogen peroxide or other oxidative stressors, and cell viability is assessed using MTT or other standard assays.
|
| Animal Protocol |
In vivo animal models for Lindleyin include the vitellogenin assay in Japanese medaka (Oryzias latipes) for estrogenic activity assessment. Male fish are exposed to Lindleyin or Lindleyin-containing extracts via water, and serum vitellogenin levels are measured as a biomarker of estrogen receptor activation. For neuroprotection studies, the MPTP-induced Parkinson's disease model in C57BL/6 mice is used. Mice are treated with Lindleyin prior to or concurrently with MPTP administration, and neuroprotective effects are assessed by measuring dopamine levels, tyrosine hydroxylase expression, and behavioral outcomes. Detailed protocols are not extensively reported.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Lindleyin include a molecular weight of 478.45 g/mol and molecular formula C23H26O11. The compound is soluble in DMSO at 100 mg/mL (209.01 mM). Storage conditions: powder at -20°C for 3 years; in solvent at -80°C for 1 year. The compound has a density of 1.497 g/cm³. Detailed PK parameters such as half-life, bioavailability, volume of distribution, and clearance are not extensively reported in the available literature. As a glycoside, its oral bioavailability and metabolism would be important considerations for in vivo studies.
|
| Toxicity/Toxicokinetics |
Detailed toxicological data for Lindleyin are not extensively reported in the available literature. As a naturally occurring phytoestrogen, its safety profile would need to be established through standard preclinical toxicity assessments. The compound is supplied as a high-purity research reagent (>99%) for laboratory use only. Given its estrogenic activity, potential endocrine-related effects would require careful evaluation in toxicological studies. Standard toxicity assessments would include evaluation of reproductive and developmental toxicity, as well as effects on hormone-sensitive tissues.
|
| References | |
| Additional Infomation |
Lindleyin is a glycoside. It has been reported to be found in rhubarb, medicinal rhubarb, and other rhubarb species with available data.
Lindleyin is also known as 莲花掌苷 in Chinese and is cataloged under CAS number 59282-56-3. It is a phenolic galloylglucoside isolated from Rhei rhizoma (rhubarb). The compound is a novel phytoestrogen that binds to ERα with estrogenic activity and acts as an agonist for both ERα and ERβ. Its estrogenic activity is completely reversed by the ER antagonist 4-hydroxytamoxifen. Beyond its phytoestrogenic properties, Lindleyin has demonstrated neuroprotective effects against oxidative stress and MPTP-induced Parkinson's disease. It is used for research purposes only, not for human consumption. |
| Molecular Formula |
C23H26O11
|
|---|---|
| Molecular Weight |
478.4459
|
| Exact Mass |
478.148
|
| CAS # |
59282-56-3
|
| PubChem CID |
42994
|
| Appearance |
White to off-white solid powder
|
| Density |
1.497g/cm3
|
| Boiling Point |
785.4ºC at 760 mmHg
|
| Flash Point |
270.1ºC
|
| Index of Refraction |
1.647
|
| Source |
Originated from plants: Polygonaceae Rheum palmatum L.
|
| LogP |
0.368
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
34
|
| Complexity |
668
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
CC(=O)CCC1=CC=C(C=C1)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)COC(=O)C3=CC(=C(C(=C3)O)O)O)O)O)O
|
| InChi Key |
BJYRNIFAMMOVGW-OXUVVOBNSA-N
|
| InChi Code |
InChI=1S/C23H26O11/c1-11(24)2-3-12-4-6-14(7-5-12)33-23-21(30)20(29)19(28)17(34-23)10-32-22(31)13-8-15(25)18(27)16(26)9-13/h4-9,17,19-21,23,25-30H,2-3,10H2,1H3/t17-,19-,20+,21-,23-/m1/s1
|
| Chemical Name |
[(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[4-(3-oxobutyl)phenoxy]oxan-2-yl]methyl 3,4,5-trihydroxybenzoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~50 mg/mL (~104.5 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (2.61 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (2.61 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 1.25 mg/mL (2.61 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0901 mL | 10.4504 mL | 20.9008 mL | |
| 5 mM | 0.4180 mL | 2.0901 mL | 4.1802 mL | |
| 10 mM | 0.2090 mL | 1.0450 mL | 2.0901 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
